185 related articles for article (PubMed ID: 25129332)
41. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
[TBL] [Abstract][Full Text] [Related]
42. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
43.
McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
[TBL] [Abstract][Full Text] [Related]
44. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
45. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
46. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
[TBL] [Abstract][Full Text] [Related]
47. [
Li B; Guo Q; Chu HQ
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Nov; 44(11):947-952. PubMed ID: 34758520
[No Abstract] [Full Text] [Related]
48. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.
Idelevich EA; Kriegeskorte A; Stubbings W; Kahl BC; Peters G; Becker K
J Antimicrob Chemother; 2011 Dec; 66(12):2809-13. PubMed ID: 21948963
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Kang SL; Rybak MJ; McGrath BJ; Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1994 Dec; 38(12):2702-9. PubMed ID: 7695250
[TBL] [Abstract][Full Text] [Related]
50. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Blondeau JM; Borsos S; Hesje CK
J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
[TBL] [Abstract][Full Text] [Related]
51. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
52. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in KwaZulu-Natal province, South Africa.
Shittu AO; Lin J
BMC Infect Dis; 2006 Jul; 6():125. PubMed ID: 16875502
[TBL] [Abstract][Full Text] [Related]
53. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Fintelmann RE; Hoskins EN; Lietman TM; Keenan JD; Gaynor BD; Cevallos V; Acharya NR
Arch Ophthalmol; 2011 Apr; 129(4):399-402. PubMed ID: 21482865
[TBL] [Abstract][Full Text] [Related]
54. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Kotlus BS; Wymbs RA; Vellozzi EM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):726-9. PubMed ID: 17056356
[TBL] [Abstract][Full Text] [Related]
55. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
[TBL] [Abstract][Full Text] [Related]
56. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
[TBL] [Abstract][Full Text] [Related]
57. In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.
Allemandi DA; Alovero FL; Manzo RH
J Antimicrob Chemother; 1994 Aug; 34(2):261-5. PubMed ID: 7814287
[TBL] [Abstract][Full Text] [Related]
58. Report-Isolation identification and control of vancomycin resistant Staphylococcus aureus.
Liaqat F; Sheikh AA; Nazir J; Hussain T; Rabbani M; Shaheen AY; Muhammad J
Pak J Pharm Sci; 2015 May; 28(3):997-1004. PubMed ID: 26004734
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
[TBL] [Abstract][Full Text] [Related]
60. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Adam HJ; Laing NM; King CR; Lulashnyk B; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2009 Nov; 53(11):4915-20. PubMed ID: 19738018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
